Journal of International Oncology››2014,Vol. 41››Issue (5): 368-370.doi:10.3760/cma.j.issn.1673-422X.2014.05.015
Previous ArticlesNext Articles
Wang Yingying, Zhu Qi
Received:
2013-12-05Revised:
2014-01-04Online:
2014-05-08Published:
2014-04-28Contact:
ZHU Qi E-mail:zhuqi70@hotmail.comWang Yingying, Zhu Qi. cAMP signaling pathway and multiple myeloma[J]. Journal of International Oncology, 2014, 41(5): 368-370.
[1] Landgren O, Korde N. Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities[J]. Oncology (Williston Park), 2011, 25(7): 589-590. [2] Insel PA, Zhang L, Murray F, et al. Cyclic AMP is both a proapoptotic and antiapoptotic second messenger[J]. Acta Physiol, 2012, 204(2):277-287. [3] Zhang L, Zambon AC, Vranizan K, et al. Gene expression signatures of cAMP/protein kinase A (PKA)promoted, mitochondrialdependent apoptosis. Comparative analysis of wildtype and cAMPdeathless S49 lymphoma cells[J]. J Biol Chem, 2008, 283(7):4304-4313. [4] Mantovani G, Bondioni S, Lania AG, et al. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells[J]. Oncogene, 2008, 27(13):1834-1843. [5] Bouizar Z, Ragazzon B, Viou L, et al. 8ClcAMP modifies the balance between PKAR1 and PKAR2 and modulates the cell cycle, growth and apoptosis in human adreoncortical H295R cells[J]. J Mol Endocrinol, 2010, 44(6):331-347. [6] FollinArbelet V, Hofgaard PO, Hauglin H, et al. Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model[J]. BMC Cancer, 2011, 11: 301. [7] Rickles RJ, Pierce LT, Giordano TP 3rd, et al. Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in Bcell malignancies[J]. Blood, 2010, 116(4):593-602. [8] 郭玉琪, Zhenfeng Duan, 张展. IL6/STAT3信号传导通路及其在肿瘤靶向治疗中的作用[J]. 国际肿瘤学杂志, 2011, 38(6):427-429. [9] FollinArbelet V, Torgersen ML, Naderi EH, et al. Death of multiple myeloma cells induced by cAMPsignaling involves downregulation of Mcl1 via the JAK/STAT pathway[J]. Cancer Lett, 2013, 335(2):323-331. [10] Song J, Li Y, Shen B. Activation of PKA pathway inhibits reactivity of human myeloma cell lineU266 to IL6[J]. Zhonghua Zhong Liu Za Zhi, 2001, 23(4):278-280. [11] Baumann P, MandlWeber S, Emmerich B, et al. Inhibition of adenosine monophosphateactivated protein kinase induces apoptosis in multiple myeloma cells[J]. Anticancer Drugs, 2007, 18(4):405-410. [12] Leone V, di Palma A, Ricchi P, et al. PGE2 inhibits apoptosis in human adenocarcinoma Caco2 cell line through RasPI3K association and cAMPdependent kinase A activation[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 293(4):G673-681. [13] McMurray JJ. Clinical practice. Systolic heart failure[J]. N Engl J Med, 2010, 362(3):228-238. [14] Misra UK, Pizzo SV. Coordinate regulation of forskolininduced cellular proliferation in macrophages by protein kinase A/cAMPresponse elementbinding protein (CREB) and Epac1Rap1 signaling: effects of silencing CREB gene expression on Akt activation[J]. J Biol Chem, 2005, 280(46):38276-38289. |
[1] | Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan.Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity, proliferation, and apoptosis of multiple myeloma cells[J]. Journal of International Oncology, 2024, 51(3): 129-136. |
[2] | Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong.Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway[J]. Journal of International Oncology, 2024, 51(1): 21-28. |
[3] | Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation, migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519. |
[4] | Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456. |
[5] | Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu.Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells[J]. Journal of International Oncology, 2023, 50(7): 413-418. |
[6] | Yang Ya, Wang Huili, Liu Yan, Guo Jinfeng, Wang Chunxia, Lyu Min, Shan Changping.Effects of GCSH gene on proliferation and apoptosis of gastric cancer SNU-1 cells[J]. Journal of International Oncology, 2023, 50(5): 257-262. |
[7] | Zhang Yuxiao, Zhang Liansheng, Li Lijuan.Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma[J]. Journal of International Oncology, 2023, 50(2): 122-125. |
[8] | Zhu Yi, Chen Jian.Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects[J]. Journal of International Oncology, 2023, 50(12): 729-733. |
[9] | Zhao Jianhao, Duan Yanchao.Research progress in the pathogenesis of extramedullary disease in multiple myeloma[J]. Journal of International Oncology, 2023, 50(1): 55-59. |
[10] | Lian Haiwei, Yang Shuorui, Liu Renzhong.Mechanism study on regulation of glioblastoma cell proliferation and apoptosis by sciadopitysin combined with CX-4945 through Notch1 pathway[J]. Journal of International Oncology, 2022, 49(6): 321-326. |
[11] | Yang Ya, Ning Xiaofei, Li Bingliang, Yao Hui, Shan Changping, Lyu Min.Study on the mechanism of procyanidin mediated anti gastric cancer SNU-1 cell line by inducing the production of reactive oxygen species[J]. Journal of International Oncology, 2022, 49(5): 257-262. |
[12] | Gao Shan, Lu Minqiu, Shi Lei, Chu Bin, Fang Lijuan, Xiang Qiuqing, Wang Yutong, Ding Yuehua, Bao Li.Clinical efficacy and safety of ixazomib-based therapy in the treatment of relapsed or refractory multiple myeloma[J]. Journal of International Oncology, 2022, 49(5): 286-291. |
[13] | Jiang Mengting, Wang Jiachun, Zong Jing.Effects of NFAT5 inhibition on proliferation, invasion, migration and apoptosis of lung adenocarcinoma cells[J]. Journal of International Oncology, 2021, 48(6): 321-327. |
[14] | Sun Ruijie, Shan Ningning.Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma[J]. Journal of International Oncology, 2021, 48(6): 381-384. |
[15] | Wang Xianwei, Shi Meiyan, Wang Fengqin, Qi Fu, Wang Chaozhe, Zhou Fei.Roles of TSA upregulation miR-4298 targeting inhibition of PADI4 expression in inducing U251 cells apoptosis[J]. Journal of International Oncology, 2021, 48(4): 193-199. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||